Samsung BioLogics Co Ltd (XKRX:207940) Share Price

Company Profile

Business description
Founded in 2011, Samsung Biologics, or Samsung Bio, is the largest contract development, research, and manufacturing organization, or CDRMO, globally in terms of manufacturing capacity. The company has 785,000 kiloliters of capacity as of 2025, with plans to acquire another 60,000 kL plant in Maryland in 2026. Samsung Bio entered the research business in June 2025, making it a full-service company offering clients preclinical, front-to-end service. It spun off Samsung Bioepis in October 2025 after its acquisition in 2022, which develops biosimilars for its own pipeline. The spinoff was meant to make Samsung Bio a pure play CDMO business. Samsung C&T and Samsung Electronics own about 43% and 31% of Samsung Bio, respectively. The company competes with Wuxi Biologics, Lonza, and Fujifilm.
Contact
300, Songdo Bio-Daero
Yeonsu-Gu
Incheon21987
KOR
T: +82 324553114
https://www.samsungbiologics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5,273

Recommended

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Solid results included strong full-self driving software uptake and positive free cash flow.

Seth Goldstein, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,012.60	41.20	0.46%
CAC 40	7,970.00	83.04	1.05%
DAX 40	26,039.68	335.66	1.31%
Dow JONES (US)	52,342.56	132.54	-0.25%
FTSE 100	10,722.07	27.57	0.26%
HKSE	22,958.65	136.18	-0.59%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	64,659.47	705.28	1.10%
NZX 50 Index	13,736.85	26.68	0.19%
S&P 500	7,720.39	23.59	-0.30%
S&P/ASX 200	8,891.80	44.50	0.50%
SSE Composite Index	3,651.43	30.04	-0.82%